#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	19	10354	16S	1529	1529	100.0	16S.l15.c4.ctg.1	2339	434.1	1	SNP	n	C1184T	0	.	.	1184	1184	C	1451	1451	C	666	C	588	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	19332	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3660	518.2	0	.	n	.	0	T695C	SNP	695	695	T	1162	1162	C	767	C,A	710,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	19332	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3660	518.2	0	.	n	.	0	G1337A	SNP	1337	1337	G	1804	1804	A	535	A	497	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	19332	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3660	518.2	0	.	n	.	0	T1971C	SNP	1971	1971	T	2438	2438	C	573	C	510	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	19332	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3660	518.2	1	SNP	n	A2045G	1	A2045G	SNP	2045	2045	A	2512	2512	G	572	G	514	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	19332	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3660	518.2	1	SNP	n	C2597T	0	.	.	2597	2597	C	3064	3064	C	599	C	534	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_P_01364c	folP.WHO_P_01364c	1	1	27	686	folP	852	852	100.0	folP.l15.c30.ctg.1	1758	37.7	1	SNP	p	R228S	1	.	.	682	684	AGC	1133	1135	AGC	80;81;83	A;G;C	72;73;75	folP.WHO_P_01364c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	1872	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3389	53.4	1	SNP	p	S91F	0	.	.	271	273	TCC	696	698	TCC	88;89;88	T;C;C	75;76;76	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	1872	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3389	53.4	1	SNP	p	D95G	0	.	.	283	285	GAC	708	710	GAC	96;96;96	G;A;C	86;86;86	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	1872	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3389	53.4	1	SNP	p	D95N	0	.	.	283	285	GAC	708	710	GAC	96;96;96	G;A;C	86;86;86	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_W_01449	mtrR.WHO_W_01449	1	1	27	578	mtrR	633	633	100.0	mtrR.l15.c4.ctg.1	1348	40.9	1	SNP	p	G45D	1	.	.	133	135	GAC	506	508	GAC	80;81;82	G;A;C	70;70;71	mtrR.WHO_W_01449:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	19	360	mtrR_promoter	250	250	100.0	mtrR_promoter.l15.c4.ctg.1	1172	29.6	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1716	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3157	52.8	1	SNP	p	D86N	0	.	.	256	258	GAC	686	688	GAC	77;76;76	G;A;C	73;71;73	parC.WHO_P_00203c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1716	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3157	52.8	1	SNP	p	S87I	0	.	.	259	261	AGT	689	691	AGT	76;79;79	A;G;T	72;76;76	parC.WHO_P_00203c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1716	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3157	52.8	1	SNP	p	S87W	0	.	.	259	261	AGT	689	691	AGT	76;79;79	A;G;T	72;76;76	parC.WHO_P_00203c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1716	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3157	52.8	1	SNP	p	S87R	0	.	.	259	261	AGT	689	691	AGT	76;79;79	A;G;T	72;76;76	parC.WHO_P_00203c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1716	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3157	52.8	1	SNP	p	S88P	0	.	.	262	264	TCC	692	694	TCC	80;81;81	T;C;C	77;78;78	parC.WHO_P_00203c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	1492	parE	1986	1986	100.0	parE.l15.c30.ctg.1	2931	49.0	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1628	1630	GGC	37;37;37	G;G,A;C	36;35,1;36	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.2.001	penA.2.001	1	1	27	1820	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2332	75.4	1	SNP	p	A311V	0	.	.	931	933	GCA	1192	1194	GCA	130;131;131	G;C;A	115;116;115	penA.2.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	1820	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2332	75.4	1	SNP	p	I312M	0	.	.	934	936	ATC	1195	1197	ATC	126;126;125	A;T;C	113;113;112	penA.2.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	1820	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2332	75.4	1	SNP	p	V316P	0	.	.	946	948	GTG	1207	1209	GTG	123;122;121	G;T;G	109;109;108	penA.2.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	1820	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2332	75.4	1	SNP	p	V316T	0	.	.	946	948	GTG	1207	1209	GTG	123;122;121	G;T;G	109;109;108	penA.2.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	1820	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2332	75.4	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1711	1713	ACC	68;68;67	A;C;C	64;66;65	penA.2.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	1820	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2332	75.4	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1765	1767	GCG	53;52;51	G;C;G	52;51;50	penA.2.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	1820	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2332	75.4	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1765	1767	GCG	53;52;51	G;C;G	52;51;50	penA.2.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	1820	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2332	75.4	1	SNP	p	G543S	0	.	.	1627	1629	GGC	1888	1890	GGC	46;45;45	G;G;C	43;43;43	penA.2.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	1820	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2332	75.4	1	SNP	p	G546S	0	.	.	1636	1638	GGC	1897	1899	GGC	36;33;33	G;G;C	34;31;32	penA.2.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	1820	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2332	75.4	1	SNP	p	P552S	0	.	.	1654	1656	CCG	1915	1917	CCG	26;26;26	C;C;G	24;25;24	penA.2.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_F_00106	ponA.WHO_F_00106	1	1	27	3222	ponA	2397	2397	99.96	ponA.l6.c4.ctg.1	3130	100.0	1	SNP	p	L421P	0	.	.	1261	1263	CTG	1572	1574	CTG	67;67;68	C,G;T;G	61,1;62;63	ponA.WHO_F_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	844	porA	1146	1146	99.83	porA.l15.c30.ctg.1	2078	39.7	0	.	p	.	0	M83fs	FSHIFT	247	247	A	532	532	C	45	C	39	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	58	porB1a	984	297	90.03	porB1a.l15.c30.ctg.1	337	7.5	0	.	p	.	0	H217N	NONSYN	649	651	CAT	63	65	AAT	2;4;4	A;A;T	2;4;4	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	58	porB1a	984	297	90.03	porB1a.l15.c30.ctg.1	337	7.5	0	.	p	.	0	D218N	NONSYN	652	654	GAT	66	68	AAT	4;4;4	A;A;T	4;4;4	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	58	porB1a	984	297	90.03	porB1a.l15.c30.ctg.1	337	7.5	0	.	p	.	0	V226A	NONSYN	676	678	GTA	90	92	GCA	5;5;5	G;C;A	5;5;5	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	58	porB1a	984	297	90.03	porB1a.l15.c30.ctg.1	337	7.5	0	.	p	.	0	.	MULTIPLE	700	702	ACT	113	115	GTA	5;5;5	G;T;A	5;5;5	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	58	porB1a	984	297	90.03	porB1a.l15.c30.ctg.1	337	7.5	0	.	p	.	0	S236N	NONSYN	706	708	AGC	119	121	AAC	5;5;5	A;A;C	5;5;5	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	58	porB1a	984	297	90.03	porB1a.l15.c30.ctg.1	337	7.5	0	.	p	.	0	N237M	NONSYN	709	711	AAC	122	124	ATG	5;5;5	A;T;G	5;5;5	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	58	porB1a	984	297	90.03	porB1a.l15.c30.ctg.1	337	7.5	0	.	p	.	0	D238fs	FSHIFT	712	712	G	125	125	G	6	G	5	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	1040	porB1b	1041	1041	96.56	porB1b.l15.c4.ctg.1	1505	66.7	0	.	p	.	0	A26V	NONSYN	76	78	GCC	402	404	GTC	72;73;72	G;T;C	68;68;68	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	1040	porB1b	1041	1041	96.56	porB1b.l15.c4.ctg.1	1505	66.7	0	.	p	.	0	E48G	NONSYN	142	144	GAA	468	470	GGA	85;85;86	G;G;A	70;70;69	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	1040	porB1b	1041	1041	96.56	porB1b.l15.c4.ctg.1	1505	66.7	0	.	p	.	0	T87A	NONSYN	259	261	ACT	585	587	GCT	62;61;61	G;C;T	59;58;58	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	1040	porB1b	1041	1041	96.56	porB1b.l15.c4.ctg.1	1505	66.7	0	.	p	.	0	T89S	NONSYN	265	267	ACC	591	593	AGC	60;60;58	A;G;C	56;57;55	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	1040	porB1b	1041	1041	96.56	porB1b.l15.c4.ctg.1	1505	66.7	0	.	p	.	0	.	MULTIPLE	358	359	AA	683	684	CG	52;49	C;G	49;47	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	1040	porB1b	1041	1041	96.56	porB1b.l15.c4.ctg.1	1505	66.7	0	.	p	.	0	.	MULTIPLE	361	362	GA	686	688	CAG	49;50;49	C;A;G	46;47;47	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	1040	porB1b	1041	1041	96.56	porB1b.l15.c4.ctg.1	1505	66.7	0	.	p	.	0	N122K	NONSYN	364	366	AAC	690	692	AAA	50;51;52	A;A;A	48;49;50	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	1040	porB1b	1041	1041	96.56	porB1b.l15.c4.ctg.1	1505	66.7	0	.	p	.	0	A125T	NONSYN	373	375	GCT	699	701	ACT	52;53;49	A;C;T	49;50;47	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	1040	porB1b	1041	1041	96.56	porB1b.l15.c4.ctg.1	1505	66.7	0	.	p	.	0	N134S	NONSYN	400	402	AAT	726	728	AGT	46;48;54	A;G;T	43;44;49	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	1040	porB1b	1041	1041	96.56	porB1b.l15.c4.ctg.1	1505	66.7	0	.	p	.	0	E137K	NONSYN	409	411	GAA	735	737	AAA	49;49;49	A;A;A	47;47;47	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	1040	porB1b	1041	1041	96.56	porB1b.l15.c4.ctg.1	1505	66.7	0	.	p	.	0	K143E	NONSYN	427	429	AAA	753	755	GAA	55;55;56	G;A;A	51;51;51	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	1040	porB1b	1041	1041	96.56	porB1b.l15.c4.ctg.1	1505	66.7	0	.	p	.	0	V151A	NONSYN	451	453	GTA	777	779	GCA	61;62;62	G;C;A	56;57;57	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	1040	porB1b	1041	1041	96.56	porB1b.l15.c4.ctg.1	1505	66.7	0	.	p	.	0	R187Q	NONSYN	559	561	CGA	885	887	CAA	143;142;141	C;A;A	122;121;122	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	1040	porB1b	1041	1041	96.56	porB1b.l15.c4.ctg.1	1505	66.7	0	.	p	.	0	N189S	NONSYN	565	567	AAC	891	893	AGC	142;142;139	A;G;C	124;123;121	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	1040	porB1b	1041	1041	96.56	porB1b.l15.c4.ctg.1	1505	66.7	0	.	p	.	0	M209I	NONSYN	625	627	ATG	951	953	ATC	124;124;123	A;T;C	110;109;108	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	1040	porB1b	1041	1041	96.56	porB1b.l15.c4.ctg.1	1505	66.7	0	.	p	.	0	E210fs	FSHIFT	628	628	G	954	954	G	123	G	108	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	1040	porB1b	1041	1041	96.56	porB1b.l15.c4.ctg.1	1505	66.7	1	SNP	p	G120K	1	.	.	358	360	AAG	683	685	CGG	52;49;49	C;G;G,A	49;47;46,1	porB1b.WHO_M_02204c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	1040	porB1b	1041	1041	96.56	porB1b.l15.c4.ctg.1	1505	66.7	1	SNP	p	D121N	0	.	.	361	363	GAC	686	689	CGC	49;49;50	C;G;C	46;47;48	porB1b.WHO_M_02204c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	1040	porB1b	1041	1041	96.56	porB1b.l15.c4.ctg.1	1505	66.7	1	SNP	p	A121D	1	.	.	361	363	GAC	686	689	CGC	49;49;50	C;G;C	46;47;48	porB1b.WHO_M_02204c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	4496	rpoB	4179	4179	99.98	rpoB.l15.c4.ctg.1	4871	90.3	1	SNP	p	H553N	1	.	.	1657	1659	AAT	2008	2010	AAT	107;108;109	A;A;T	97;99;100	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	384	rpsJ	312	312	100.0	rpsJ.l15.c17.ctg.1	1115	33.6	1	SNP	p	V57M	1	.	.	169	171	ATG	543	545	ATG	74;72;73	A;T;G	68;66;67	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
